Radioactive therapy offers new hope for hard-to-treat kidney cancer
NCT ID NCT06959433
First seen Apr 05, 2026 · Last updated May 05, 2026 · Updated 3 times
Summary
This study tests a radioactive drug called Lu-177 PSMA in 20 adults with metastatic clear cell kidney cancer that has worsened after at least two prior treatments. The drug targets a protein found on cancer cells and their blood vessels, aiming to control the disease. Researchers will monitor side effects and tumor response using standard criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.